Proton Radiation For Meningiomas and Hemangiopericytomas

Meningioma Clinical Trial

Official title:

Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01117844
• Other study ID #: UPCC 24309
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: February 4, 2010
• Est. completion date: December 2024

Study information

• Verified date: December 2023
• Source: Abramson Cancer Center at Penn Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Feasibility/Phase II study for patients with a diagnosis of WHO Grade I - III Meningioma & Hemangiopericytoma brain cancer to be given standard dose Proton radiotherapy. The study will be performed in two phases: first, feasibility with an enrollment of 12 patients and then Phase Page 8 of 20 II, with an enrollment of an additional 38 patients. All patients will also be given quality of life (QOL) instruments pretreatment, weekly during treatment, then q 3 months for year 1 post treatment, q6 months year 2 & 3 and yearly for year 4 & 5. Comparisons will be made between the enrolled subjects receiving proton therapy and the known literature on photon radiation. See section 2 for full objectives. The second phase will begin no earlier than 60 days after the last patient in the initial phase has completed treatment and once safety and feasibility has been verified. The secondary objectives will serve as the objectives for the second phase of the study.

Description:

Primary Objectives:

The primary objectives of this study are feasibility and safety. The study will be deemed infeasible if greater than 10% of pts experience one of the following:

• Patient cannot be given treatment because anatomy is such that a dosimetrically satisfactory treatment plan cannot be devised.

(95% of target volume covered by 95% of the dose)

• Patient is unable to tolerate 20% of treatments (for any reason unable to set patient up within acceptable limits of tolerance, patient unable to tolerate treatment position or immobilization for duration of treatment) using proton radiotherapy (up to 80% of treatments could be delivered using photons).

• Patient is unable to complete all of his/her treatments within 7 days of estimated date of treatment completion or requires a treatment break greater than 5 days. Toxicity will be deemed unacceptable if greater than 20% of patients experience acute toxicity, as defined in Section 7.12.

Secondary Objectives:

• To assess acute side effects from irradiation using proton beam therapy in place of conventional photon beam therapy for the treatment of meningiomas.

• To assess quality of life outcomes, with a focus on the rate of severe fatigue at 6 and 12 months from end of treatment.

• To assess late complications from irradiation using proton beam therapy in place of conventional photon beam therapy for the treatment of meningiomas.

• To compare the dose distribution to tumor and surrounding normal structures using DVHs (Dose Volume Histograms) generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes.

• To determine 1-yr local control and progression-free and overall survival using proton radiotherapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: December 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed diagnosis of WHO I-III meningiomas and hemangiopericytomas:

1. WHO grade I :

• Tumor that are newly diagnosed and tumors that are incompletely excised

• Tumors that have recurred post resection

2. WHO grade II:

• Any tumor, either completely or incompletely excised

• Any recurrent tumor

3. WHO grade III and hemangiopericytoma:

• Any tumor, either completely or incompletely excised

• Any recurrent tumor

• Patients must have a Karnofsky Performance Status of 60. Age greater than 18 years Patients must be able to provide informed consent.

• Adequate bone marrow function: WBC greater than 4000/mm3, platelets greater than 100,000 mm3.

• Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods etc.). Hysterectomy or menopause must be clinically documented.

Exclusion Criteria:

• Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma).

• Pregnant women, women planning to become pregnant and women that are nursing. Actively being treated on any other therapeutic research study.

• Prior radiation to the brain.

Related Conditions & MeSH terms

• Hemangiopericytoma
• Meningioma
• Solitary Fibrous Tumors

Intervention

Radiation:
• Proton Radiation
Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the Unviersity of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility and Safety	For proton to deemed feasible, no greater than 10% of patients should experience a) Patient cannot be given treatment because anatomy is such that a dosimetically satisfactory treatment plan cannot be devised, b) Patient is unable to tolerate 20% of treatments using proton therapy, and c) patient is unable to complete all treatments within 7 days of estimated date of treatment completion	90 days
Secondary	Late Toxicity	Late toxicity is defined as any grade 3 or higher toxicity, excluding seizures, observed later than 90 days from start of radiation therapy.	90 days
Secondary	Fatigue - Brief Fatigue Inventory (BFI)	Fatigue will be scored by the Brief Fatigue Inventory (BFI), a validated instrument, which will be evaluated at the following time points: Pre-radiation, weekly during treatment, at 3, 6, 9, 12 months post-radiation and then every 6 months. It is expected that BFI score will increase (as fatigue worsens) in the first 6-9 months post-radiation and then the BFI score will decrease (as fatigue improves) at 12-24 months post-radiation. Proton radiotherapy is expected to improve fatigue as compared to photon radiotherapy.	5 Years
Secondary	Health Related Quality of Life	Health Related Quality of Life will be followed using the following: EQ-5D European Quality of Life Index, Fact-G Functional Assessment of Cancer Therapy-General (FACT-G), and Fact-BR Functional Assessment of Cancer Therapy-Brain. Fact-BR will be evaluated at the same time points as the BFI. EQ-5D and Fact-G will be evaluated at pre-radiation, at 3, 6, 9, 12 months postradiation and then every 6 months.	5 Years
Secondary	Cumulative total dose (Gy) to normal brain tissue	Cumulative total dose (Gy) to normal brain tissue will be estimated based on dosimetry plans for both proton and photon. Proton radiotherapy is expected to decrease exposure to normal brain tissues.	8 Weeks
Secondary	Progression free survival (PFS) and overall survival (OS)	PFS and OS are defined as the time from start of radiotherapy to first documented progression (event for PFS), death due to any cause or last patient contact alive.	5 Years